UBS O'Connor’s ACELYRIN SLRN Stock Holding History

UBS O'Connor’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,500	Closed	-$4.71K	–	589
2023 Q3	$4.71K	Buy	+14,500	New	+$308K	﹤0.01%	539

Other funds holding SLRN

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

UBS O'Connor's SLRN Position: Q1 2025 in Review

UBS O'Connor sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 211,938 shares — an estimated $665K sold.

UBS O'Connor first reported a position in SLRN in Q4 2023 and held it in 5 quarters. The position peaked at $807K in Q3 2024. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

UBS O'Connor reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
UBS O'Connor sold 211,938 ACELYRIN shares in Q1 2025, an estimated $665K.
UBS O'Connor first reported a position in ACELYRIN in Q4 2023 and held it in 5 quarters.
UBS O'Connor's ACELYRIN position peaked at $807K in Q3 2024.
105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.